Suppr超能文献

中国北方大量B基因型和C基因型乙型肝炎病毒感染患者耐药突变的检出率及突变模式比较

Comparison of Detection Rate and Mutational Pattern of Drug-Resistant Mutations Between a Large Cohort of Genotype B and Genotype C Hepatitis B Virus-Infected Patients in North China.

作者信息

Li Xiaodong, Liu Yan, Xin Shaojie, Ji Dong, You Shaoli, Hu Jinhua, Zhao Jun, Wu Jingjing, Liao Hao, Zhang Xin-Xin, Xu Dongping

机构信息

1 Research Center for Clinical and Translational Medicine , Beijing 302 Hospital, Beijing, China .

2 Medical Center for Liver Failure , Beijing 302 Hospital, Beijing, China .

出版信息

Microb Drug Resist. 2017 Jun;23(4):516-522. doi: 10.1089/mdr.2016.0093. Epub 2016 Oct 28.

Abstract

The study aimed to investigate the association of prevalent genotypes in China (HBV/C and HBV/B) with HBV drug-resistant mutations. A total of 13,847 nucleos(t)ide analogue (NA)-treated patients with chronic HBV infection from North China were enrolled. HBV genotypes and resistant mutations were determined by direct sequencing and confirmed by clonal sequencing if necessary. HBV/B, HBV/C, and HBV/D occupied 14.3%, 84.9%, and 0.8% across the study population, respectively. NA usage had no significant difference between HBV/B- and HBV/C-infected patients. Lamivudine-resistant mutations were more frequently detected in HBV/C-infected patients, compared with HBV/B-infected patients (31.67% vs. 25.26%, p < 0.01). Adefovir- and entecavir-resistant mutation detection rates were similar, but the mutational pattern was different between the two genotypes. For adefovir-resistant mutations, HBV/C-infected patients had a higher detection rate of rtA181 V (HBV/C 5.29% vs. HBV/B 1.36%, p < 0.01) and a lower detection rate of rtN236T (2.70% vs. 6.54%, p < 0.01). For entecavir-resistant mutations, HBV/C-infected patients had a higher detection rate of rtM204 V/I+T184 substitution or S202G/C (3.66% vs. 2.16%, p < 0.01) and a lower detection rate of rtM204 V/I+M250 V/I/L substitution (0.67% vs. 1.46%, p < 0.01). Multidrug-resistant mutations (defined as coexistence of mutation to nucleoside and nucleotide analogues) were detected in 104 patients. HBV/C-infected patients had a higher detection rate of multidrug-resistant mutation than HBV/B-infected patients (0.83% vs. 0.35%, p < 0.05). The study for the first time clarified that HBV/C-infected patients had a higher risk to develop multidrug-resistant mutations, compared with HBV/B-infected patients; and HBV/C- and HBV/B-infected patients had different inclinations in the ETV-resistant mutational pattern.

摘要

该研究旨在调查中国流行的基因型(HBV/C和HBV/B)与乙肝病毒耐药突变之间的关联。共纳入了13847例来自中国北方接受核苷(酸)类似物(NA)治疗的慢性乙肝病毒感染患者。通过直接测序确定乙肝病毒基因型和耐药突变,必要时通过克隆测序进行确认。在整个研究人群中,HBV/B、HBV/C和HBV/D分别占14.3%、84.9%和0.8%。HBV/B感染患者和HBV/C感染患者之间的NA使用情况无显著差异。与HBV/B感染患者相比,在HBV/C感染患者中更频繁地检测到拉米夫定耐药突变(31.67%对25.26%,p<0.01)。阿德福韦和恩替卡韦耐药突变的检测率相似,但两种基因型之间的突变模式不同。对于阿德福韦耐药突变,HBV/C感染患者rtA181V的检测率较高(HBV/C为5.29%对HBV/B为1.36%,p<0.01),而rtN236T的检测率较低(2.70%对6.54%,p<0.01)。对于恩替卡韦耐药突变,HBV/C感染患者rtM204V/I+T184替代或S202G/C的检测率较高(3.66%对2.16%,p<0.01),而rtM204V/I+M250V/I/L替代的检测率较低(0.67%对1.46%,p<0.01)。在104例患者中检测到多重耐药突变(定义为对核苷和核苷酸类似物的突变共存)。HBV/C感染患者的多重耐药突变检测率高于HBV/B感染患者(0.83%对0.35%,p<0.05)。该研究首次阐明,与HBV/B感染患者相比,HBV/C感染患者发生多重耐药突变的风险更高;并且HBV/C感染患者和HBV/B感染患者在恩替卡韦耐药突变模式上有不同倾向。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验